ondasdechoque.org
PT-BR

How tendons respond to shockwaves: animal and cell studies · Lab study · 2022

How do injured tendons respond to shockwave in animal and lab studies?

This review gathers studies in rats, rabbits, dogs, horses and cells. In recently injured tendons, low-energy shockwave was followed by more new blood vessels, more cell activity and more collagen, the building block of tendon, with calmer inflammation. Higher doses damaged the tendon.

Explores how shockwave works
animal species studied: horses, rats, rabbits and dogs
4
study measuring short-term chemical changes in human tendons
1
year published
2022

Good to know: Most tendons were injured on purpose for the experiments.

Chen Y, Lyu K, Lu J, et al. Frontiers in Veterinary Science, 2022 · Read the paper ↗

The treatment

Experimental exposures in Table 2
As printed: ponies 0.14 mJ/mm², 600 impulses; rats 0.16 mJ/mm², 0, 200, 500 or 1,000 impulses; rats 0.36 mJ/mm², 50 or 100 impulses; rats 500 shocks in 5 minutes at 15 kV; dogs 0.18 mJ/mm², 1,000 impulses; dogs 0.03 or 0.1 mJ/mm², 500 impulses; rabbits 0.12 mJ/mm², 500 impulses, and three doses of 0.12–0.14 mJ/mm² at 15 Hz over 28 days; cultured cells 0.03–0.19 mJ/mm² with 10 to 1,500 pulses; human tendons 2,500 impulses at 8 Hz.
Dose ceilings stated by the review
The review states that energy flux densities above 0.28 mJ/mm² are not recommended clinically for tendinopathy, citing a rat study of tendon damage, and that tolerance differs by species and tendon (rabbit quadriceps tendon damaged above 0.5 mJ/mm²). It notes that most doses have been set empirically.
Clinical protocols mentioned
Examples as printed: focused 0.08 mJ/mm², 3,000 shocks, and 0.29 mJ/mm², 1,500 shocks (plantar fasciitis); radial 400 pulses at 12 Hz and 2.0 bar (plantar fasciitis); 0.09 mJ/mm² at 4 Hz (lateral epicondylitis); 0.32 mJ/mm² × 1,500 versus 0.08 mJ/mm² × 6,000 (calcific tendinitis); focused 0.12 mJ/mm² versus radial 2.4 bar, 2,000 each (patellar tendinopathy).

Who took part

Earlier research in horses, rats, rabbits and dogs, mostly with surgically or chemically injured Achilles tendons, plus cells grown in the lab and a few clinical trials.

Side effects

In clinical use: brief pain, mild swelling and redness at the treated spot. In animals, higher doses damaged tendons.

All the numbers and the full appraisal
FROM THE FULL PAPER

What the full paper reports.

Published studies on tendinopathy and tendon repair: clinical trials in plantar fasciitis, lateral epicondylitis, calcific shoulder tendinitis and patellar and Achilles tendinopathy, and 13 tabulated experiments in ponies, rats, rabbits and dogs (mostly surgically or chemically injured Achilles tendons), cultured human and animal cells, and one microdialysis study in human tendons.

New blood vessels in the inflammatory phase1 reported outcome
01
Hours to 8 weeks after exposure, by study

New blood vessels in the inflammatory phase

New blood vessels in the inflammatory phase Narrative finding

In dogs with Achilles tenotomy (0.18 mJ/mm², 1,000 impulses) new capillaries were found in all samples at 4 and 8 weeks; in rabbits (0.12 mJ/mm², 500 impulses) vessel numbers, eNOS, VEGF and PCNA rose; in horses, treated injured flexor tendons had more capillaries than untreated ones. In cultured human umbilical vein cells (800 shots at 0.03 mJ/mm²) VEGF, eNOS, Erk1/2, Akt, caveolin-1 and β1-integrin rose. Proposed routes are endothelial progenitor-cell migration via HIF-1α, SDF-1 and VEGF, a mechanosensing complex, caveolae and MMP-9.

Analysis details and source

Animal and cell findings as summarized by the review; not a human treatment effect.

Cell proliferation and collagen synthesis1 reported outcome
02
3 hours to 12 weeks after exposure, by study

Cell proliferation and collagen synthesis

Cell proliferation and collagen synthesis Narrative finding

In rats (0.16 mJ/mm²), PCNA, TGF-β1, IGF-I and vessel numbers rose; 200 pulses promoted healing of collagenase-induced tendinitis, whereas more than 200 inhibited repair. In rats given 0.36 mJ/mm² (50 or 100 impulses), PCNA rose at 6 and 24 hours, NO and TGF-β1 at 24 hours, and collagen synthesis by day 7. Tenotomy models in rabbits and rats showed more proliferation, collagen synthesis and, in one rat study, tensile strength; in ponies, matrix genes shifted (MMP3 down and MMP13 up at 3 hours; COL1, MMP13 and MMP14 up at 6 weeks). Cultured human tenocytes grew more and made more collagen.

Analysis details and source

Dose dependence (200 versus more than 200 pulses) is from one rat study as summarized in Table 2; the same row labels the model “Achilles tenotomy” while its conclusion refers to collagenase-induced tendinitis.

Inflammation in the remodelling phase1 reported outcome
03
As reported in the source

Inflammation in the remodelling phase

Inflammation in the remodelling phase Narrative finding

Proposed anti-inflammatory routes are moderate nitric-oxide production with NF-κB inhibition (dogs, 0.03 or 0.1 mJ/mm²), TLR3 signalling with an early IL-6 and later IL-10 response, reduced CGRP and substance P, and a macrophage shift from M1 to M2. In horses with lower-limb skin wounds treated at 0.11 mJ/mm², untreated controls were reported as 1.9 times more likely to show inflammation. In contrast, a sheep study found no histological change in SP- and CGRP-containing fibres after treatment, and the authors write that more evidence is needed on this point.

Analysis details and source

The horse result concerns skin wounds, not tendons; the 1.9 figure is quoted from the review without its uncertainty.

Short-term chemistry in human tendons1 reported outcome
04
1 to 4 hours after exposure

Short-term chemistry in human tendons

Short-term chemistry in human tendons Narrative finding

The only direct human in vivo measurement in Table 2 is a microdialysis study of Achilles and patellar tendons (2,500 impulses at 8 Hz) that found higher IL-6, IL-8, MMP-2 and MMP-9 within 4 hours. The review reads this as support for inflammatory and catabolic clearing of damaged matrix; it is a short-term biochemical change, not a clinical outcome.

Analysis details and source

Table 2 labels this study “In vitro” while the text and the reference title describe it as in vivo in humans; total energy is printed as “160 mJ/mm”.

Higher doses and tendon damage1 reported outcome
05
As reported in the source

Higher doses and tendon damage

Higher doses and tendon damage Narrative finding

A rat study found fibrinoid necrosis, paratendinous fibrosis and inflammatory-cell infiltration in normal tendons after high-energy shock waves. The review states that rabbit and rat Achilles tendons showed damage at 0.28 and 0.2 mJ/mm², and rabbit quadriceps tendon above 0.5 mJ/mm².

Analysis details and source

The sentence on rabbit and rat thresholds cites references 4 and 57, which the reference list gives as two studies in ponies; the source of those thresholds is therefore unclear.

Clinical results quoted by the review1 reported outcome
06
Varied by trial; often 3 months

Clinical results quoted by the review

Clinical results quoted by the review Narrative finding

The review quotes favourable trials (for example, in lateral epicondylitis 65% of treated versus 28% of sham patients had at least 50% pain reduction) and trials with similar results in both arms (in a multicentre lateral epicondylitis trial, 3-month success of 25.8% or 31.7% with shockwave versus 25.4% and 33.1% with placebo; and a few plantar fasciitis trials (three references, including Buchbinder et al.) with non-positive results). A steroid injection improved symptoms more than shockwave at 3 months in one trial, and patellar tendinopathy results conflict.

Analysis details and source

Narrative quotations of selected trials; the overall success range of 65–91% and the Table 1 statements are the review’s summary, not effect estimates, and were not checked against the original trials.

How treatment was delivered
Experimental exposures in Table 2

As printed: ponies 0.14 mJ/mm², 600 impulses; rats 0.16 mJ/mm², 0, 200, 500 or 1,000 impulses; rats 0.36 mJ/mm², 50 or 100 impulses; rats 500 shocks in 5 minutes at 15 kV; dogs 0.18 mJ/mm², 1,000 impulses; dogs 0.03 or 0.1 mJ/mm², 500 impulses; rabbits 0.12 mJ/mm², 500 impulses, and three doses of 0.12–0.14 mJ/mm² at 15 Hz over 28 days; cultured cells 0.03–0.19 mJ/mm² with 10 to 1,500 pulses; human tendons 2,500 impulses at 8 Hz.

Dose ceilings stated by the review

The review states that energy flux densities above 0.28 mJ/mm² are not recommended clinically for tendinopathy, citing a rat study of tendon damage, and that tolerance differs by species and tendon (rabbit quadriceps tendon damaged above 0.5 mJ/mm²). It notes that most doses have been set empirically.

Clinical protocols mentioned

Examples as printed: focused 0.08 mJ/mm², 3,000 shocks, and 0.29 mJ/mm², 1,500 shocks (plantar fasciitis); radial 400 pulses at 12 Hz and 2.0 bar (plantar fasciitis); 0.09 mJ/mm² at 4 Hz (lateral epicondylitis); 0.32 mJ/mm² × 1,500 versus 0.08 mJ/mm² × 6,000 (calcific tendinitis); focused 0.12 mJ/mm² versus radial 2.4 bar, 2,000 each (patellar tendinopathy).

HARMS & TOLERABILITY

The review lists complications reported in clinical use as partial or residual pain, mild oedema and transient erythema at the application site, without event counts. Animal data show tendon damage at higher doses, although the sentence on rabbit and rat thresholds cites two pony studies. It also raises concern that unsupervised use by lay people may lead to misuse in horses. Funding: Southwest Medical University, its affiliated hospital and Luzhou city science programmes; the authors declare no conflicts, and no device-maker ties are stated.

LIMITS OF THE ANALYSIS

Author-reported: most doses have been set empirically, treatment parameters are not uniform across studies, placebo control groups and long follow-up are needed, and further in vivo studies of the biological response are required.

Extractor interpretation: a single-database search that admitted reviews, with no quality or risk-of-bias appraisal and no extraction of effect sizes; the clinical summaries in the text and Table 1 cannot be taken as measured benefit.

Extractor interpretation: labelling and citation inconsistencies. The title says “in vivo” but Table 2 includes cell cultures and a human foreskin model; the human microdialysis study is labelled “in vitro”; one row calls a collagenase model a tenotomy; the review cites the same microdialysis paper twice (refs. 2 and 54); and the rabbit and rat damage thresholds cite pony studies.

Extractor interpretation: most mechanistic data come from acutely injured, otherwise healthy animal tendons (tenotomy or collagenase), which differ from chronic human tendinopathy; the only human mechanistic data in the table are short-term chemical changes.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Author-reported: most doses have been set empirically, treatment parameters are not uniform across studies, placebo control groups and long follow-up are needed, and further in vivo studies of the biological response are required.
  • Extractor interpretation: a single-database search that admitted reviews, with no quality or risk-of-bias appraisal and no extraction of effect sizes; the clinical summaries in the text and Table 1 cannot be taken as measured benefit.
  • Extractor interpretation: labelling and citation inconsistencies. The title says “in vivo” but Table 2 includes cell cultures and a human foreskin model; the human microdialysis study is labelled “in vitro”; one row calls a collagenase model a tenotomy; the review cites the same microdialysis paper twice (refs. 2 and 54); and the rabbit and rat damage thresholds cite pony studies.
  • Extractor interpretation: most mechanistic data come from acutely injured, otherwise healthy animal tendons (tenotomy or collagenase), which differ from chronic human tendinopathy; the only human mechanistic data in the table are short-term chemical changes.
Research review

Source-linked critical reading

Narrative review of animal, cell and selected clinical studies

Reading depthMaterial consulted
Technical source record

Full local PDF read: all 16 pages including the search strategy and flow chart, Tables 1–2, Figures 1–5 and captions, acknowledgments (funding), conflict-of-interest statement and 108 references. Underlying trials and experiments were not re-read.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Narrative review of tendon-repair mechanisms based on a PubMed/MEDLINE search (1979–2022) that included reviews and experimental papers (106 articles), without quality or risk-of-bias appraisal. It summarizes selected clinical trials and tabulates 13 animal, cell and human-tissue experiments; no pooled estimate.

Participants and setting

Published studies on tendinopathy and tendon repair: clinical trials in plantar fasciitis, lateral epicondylitis, calcific shoulder tendinitis and patellar and Achilles tendinopathy, and 13 tabulated experiments in ponies, rats, rabbits and dogs (mostly surgically or chemically injured Achilles tendons), cultured human and animal cells, and one microdialysis study in human tendons.

Treatment protocol

No treatment was given by the authors. Table 2 experiments used 0.03–0.36 mJ/mm² and 10 to 2,500 pulses, with one rat study given in kV; the review states that energies above 0.28 mJ/mm² are not recommended clinically for tendinopathy and that most doses have been set empirically.

Comparison

Experiments mostly compare treated with untreated tendons or different pulse numbers. The clinical trials cited had sham, surgery, steroid-injection or different-dose comparators, but the review neither extracts their effect sizes nor appraises their quality.

What was measured

Tissue and molecular markers in animal and cell experiments: vessel counts, eNOS, VEGF, MMPs, PCNA, TGF-β1, IGF-I, nitric oxide, IL-6, collagen synthesis, tensile strength, NF-κB, TLR3, CGRP and substance P, and macrophage type. Clinical success rates and pain or function results are quoted from selected trials, not extracted.

Results and interpretation

Animal and cell studies report more new blood vessels, eNOS, VEGF and PCNA, higher TGF-β1, IGF-I, nitric oxide and IL-6, more collagen synthesis and lower inflammatory signals after low-energy exposure. Effects depended on dose: in rats, 200 pulses aided healing whereas more than 200 inhibited repair, and higher energies damaged tendons in animals. In sheep, one study found no histological change in SP- and CGRP-containing nerve fibres. The clinical results cited are mixed, including sham-controlled trials in which shockwave and sham gave similar results.

Harms and disclosures

The review lists complications reported in clinical use as partial or residual pain, mild oedema and transient erythema at the application site, without event counts. Animal data show tendon damage at higher doses, although the sentence on rabbit and rat thresholds cites two pony studies. It also raises concern that unsupervised use by lay people may lead to misuse in horses. Funding: Southwest Medical University, its affiliated hospital and Luzhou city science programmes; the authors declare no conflicts, and no device-maker ties are stated.

Limitations

The authors note that doses were set empirically, parameters vary and placebo control and long follow-up are needed. The search covered one database, admitted reviews and had no quality appraisal, so its clinical summaries are not measured benefit. Table 2 mixes cell, animal and human-tissue work under an “in vivo” title, mislabels the human microdialysis study, cites pony studies for rabbit and rat damage thresholds, and draws mainly on acute injury models unlike chronic human tendinopathy.

Applicability

Useful as a map of the tendon-repair pathways proposed from animal and cell work. Species, injury models and doses vary widely, so it cannot set a human dose, predict who improves or estimate clinical benefit.

What stronger evidence needs

Controlled studies in people with chronic tendinopathy that measure the proposed markers (new vessels, collagen, inflammatory mediators) at defined doses with sham control, and link them to blinded pain and function outcomes over long follow-up.

THE ORIGINAL SOURCE

Read the original article.

Biological response of extracorporeal shock wave therapy to tendinopathy in vivo (review)

Chen Y, Lyu K, Lu J, Jiang L, Zhu B, Liu X, Li Y, Liu X, Long L, Wang X, Xu H, Wang D, Li S. · Frontiers in veterinary science · 2022

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →